orlistat

网络  奥利司他; 奧利司他; 奥利司它; 奥利斯他; 奥利斯特

医学



双语例句

  1. If you stop taking orlistat, continue with your diet and exercise program.
    停用此产品后,务必持续配合良好的饮食习惯以及持续的运动。
  2. Orlistat gives many people diarrhea, but the only side effect of walking is good health.
    Orlistat让许多人腹泄,但步行的唯一负作用是良好的健康。
  3. The Food and Drug Administration said the fat-blocking weight-loss pill orlistat, which has been available by prescription, can be sold in a reduced-strength version over the counter.
    食品药品管理局说,阻止脂肪摄入的减肥药奥里斯特,曾经是处方药,现在以减少长度的形式作为非处方药。
  4. Effects of orlistat on endothelium-independent vasodilation function in obese subjects with hypertension
    奥利司他对肥胖高血压患者非内皮依赖性血管舒张功能的影响
  5. The American Food and Drug Administration ( FDA) has approved Orlistat for use as an over the counter weight loss drug for adults who are overweight.
    美国食品与药品管理局(FDA)批准将奥利司他作为治疗成人超重的非处方药。
  6. Orlistat blocks the intestines from absorbing fat when taken up to three times a day with meals.
    在每天三次随同吃饭时的服用奥利司他,可以阻隔肠子吸收脂肪。
  7. Treatment with orlistat is associated with frequent gastrointestinal side effects, sibutramine may raise blood pressure and heart rate, and rimonabant may increase the risk of mood disorders.
    奥利斯特治疗伴随有频繁的胃肠道副作用,西布曲明可能会带来血压和心率的升高,利莫那班则可能增加心理障碍的发病率。
  8. Conclusions: Orlistat alters gastric and gallbladder emptying and reduces the postprandial secretion of GLP-1, PYY and CCK.
    结论:奥利斯特改变了胃和胆囊排空,并减少GLP-1,PYY和CCK的餐后分泌。
  9. Orlistat for adjutant treatment of fatty type 2 diabetes mellitus in 32 patients
    奥利司他辅助治疗肥胖2型糖尿病32例
  10. Women in both groups experienced significant decreases in body mass index ( BMI), waist circumference, and waist-hip ratio after treatment with orlistat, the authors report.
    报道称,两组女性接受奥利斯他的治疗后,体重指数,腰围,腰臀比均有明显的下降。
  11. Use of Orlistat ( Xenical) to treat chylous ascites
    奥利斯他(赛尼可)治疗乳糜腹水的有效性
  12. A new antiobesity drug& orlistat
    新型抗肥胖药奥利司他
  13. Effects of micronized fenofibrate on low density lipoprotein subfraction profiles in type IV hyperlipidemic subjects Changes of LDL subfraction of obese patients treated with orlistat: a double-blind, placebo-controlled clinical trial
    随机、双盲、安慰剂对照研究奥利司他对肥胖患者血清小而密低密度脂蛋白的影响
  14. Objective To evaluate the efficacy and safety of orlistat combined with low calorie diet in the treatment of obesity with non-alcoholic fatty liver disease.
    目的评价奥利司他结合低热卡饮食在治疗肥胖伴非酒精性脂肪性肝病(NAFLD)中的作用。
  15. Objective To evaluate the clinical efficacy and safety of orlistat in Chinese overweight and obese patients.
    目的对奥利司他(orlistat;商品名:赛尼可)在中国超重和肥胖症患者中的临床疗效及安全性进行评价。
  16. Quinapril and orlistat were used as the model for the verification of the developed method respectly.
    分别以喹那普利和奥利司他为模型对本方法进行验证。